Form 8-K - Current report:
SEC Accession No. 0001193125-25-004080
Filing Date
2025-01-10
Accepted
2025-01-10 07:30:22
Documents
15
Period of Report
2025-01-09
Items
Item 2.02: Results of Operations and Financial Condition
Item 2.05: Cost Associated with Exit or Disposal Activities
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d906527d8k.htm   iXBRL 8-K 61426
2 EX-99.1 d906527dex991.htm EX-99.1 37350
6 GRAPHIC g906527g0110034504806.jpg GRAPHIC 6798
  Complete submission text file 0001193125-25-004080.txt   246702

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA ntla-20250109.xsd EX-101.SCH 2847
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE ntla-20250109_lab.xml EX-101.LAB 17994
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ntla-20250109_pre.xml EX-101.PRE 11259
17 EXTRACTED XBRL INSTANCE DOCUMENT d906527d8k_htm.xml XML 3630
Mailing Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139
Business Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139 857-285-6200
Intellia Therapeutics, Inc. (Filer) CIK: 0001652130 (see all company filings)

EIN.: 364785571 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37766 | Film No.: 25520419
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)